190 related articles for article (PubMed ID: 24971906)
1. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Rønø B; Rømer J; Liu S; Bugge TH; Leppla SH; Kristjansen PE
Mol Cancer Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16432166
[TBL] [Abstract][Full Text] [Related]
3. Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Wein AN; Liu S; Zhang Y; McKenzie AT; Leppla SH
Invest New Drugs; 2013 Feb; 31(1):206-12. PubMed ID: 22843210
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
7. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Schafer JM; Peters DE; Morley T; Liu S; Molinolo AA; Leppla SH; Bugge TH
PLoS One; 2011; 6(5):e20532. PubMed ID: 21655226
[TBL] [Abstract][Full Text] [Related]
8. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
10. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100
[TBL] [Abstract][Full Text] [Related]
11. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Liu S; Bugge TH; Leppla SH
J Biol Chem; 2001 May; 276(21):17976-84. PubMed ID: 11278833
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.
Mackowiak da Fonseca J; Mackowiak da Fonseca II; Nagamine MK; Massoco CO; Nishiya AT; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987941
[TBL] [Abstract][Full Text] [Related]
13. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
[TBL] [Abstract][Full Text] [Related]
14. Tumor Targeting and Drug Delivery by Anthrax Toxin.
Bachran C; Leppla SH
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376328
[TBL] [Abstract][Full Text] [Related]
15. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Liu S; Redeye V; Kuremsky JG; Kuhnen M; Molinolo A; Bugge TH; Leppla SH
Nat Biotechnol; 2005 Jun; 23(6):725-30. PubMed ID: 15895075
[TBL] [Abstract][Full Text] [Related]
16. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
[TBL] [Abstract][Full Text] [Related]
17. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA; Liu S; Bugge TH; Torres JB; Mosley M; Hopkins SL; Allen PD; Berridge G; Vendrell I; Fischer R; Kersemans V; Smart S; Leppla SH; Cornelissen B
J Nucl Med; 2019 Oct; 60(10):1474-1482. PubMed ID: 30954944
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Alfano RW; Leppla SH; Liu S; Bugge TH; Herlyn M; Smalley KS; Bromberg-White JL; Duesbery NS; Frankel AE
Mol Cancer Ther; 2008 May; 7(5):1218-26. PubMed ID: 18483309
[TBL] [Abstract][Full Text] [Related]
19. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
20. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
